Join
Live feed
·
PRReleasevia Quantisnow
Bio-Path Holdings Inc. logo

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

ByQuantisnow·Wall Street's wire, on your screen.
BPTH· Bio-Path Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BPTH (Bio-Path Holdings Inc.) and more on Quantisnow.